RGRX.US Regenerx Biopharm In

Healthcare Biotechnology USA Stocks
0.0011 USD
Close of Nov 18, 2026
0.0002 0.0011
Market cap
USD 1.65K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2023.

Is RGRX.US undervalued?

Graham number

The Graham number of Regenerx Biopharm In cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regenerx Biopharm In fundamental analysis

No fundamental analysis for Regenerx Biopharm In yet.

Regenerx Biopharm In stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regenerx Biopharm In

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB T…

Full company profile